1
Clinical Trials associated with IB160-adjuvanted H5N8 cell culture-derived influenza vaccine(Butantan Institute)Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial To Evaluate The Safety And Immunogenicity Of The Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) From Instituto Butantan, In Adults And The Older Adults
This study aims to demonstrate the safety and immunogenicity of two formulations of the monovalent influenza vaccine candidate A (H5N8) (inactivated, fragmented, and adjuvanted with IB160) from the Instituto Butantan in adults and older adults, to be developed for situations of pandemic, epidemic or outbreak of avian type A/H5 in humans, in the context of pandemic preparedness.
100 Clinical Results associated with IB160-adjuvanted H5N8 cell culture-derived influenza vaccine(Butantan Institute)
100 Translational Medicine associated with IB160-adjuvanted H5N8 cell culture-derived influenza vaccine(Butantan Institute)
100 Patents (Medical) associated with IB160-adjuvanted H5N8 cell culture-derived influenza vaccine(Butantan Institute)
100 Deals associated with IB160-adjuvanted H5N8 cell culture-derived influenza vaccine(Butantan Institute)